Funding
Strategic · Biotech

General Proximity raises $20m in strategic financing

FreeMind Investments and Daewoong Pharmaceutical participated in the financing.

Updated Oct 16, 2026By RoundOS Funding desk

General Proximity raised $20 million in strategic financing on May 4, with participation from FreeMind Investments and Daewoong Pharmaceutical. The company develops induced-proximity medicines for oncology and cardiometabolic disease.

Funding history

Strategic · This round$20M

Sources

  1. General Proximityprojectstartups.com
  2. prnewswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026

Related